trastuzumab deruxtecan
daiichi sankyo,AstraZeneca
['rux,(-crux),(-trux)', 'fam-trastuzumab deruxtecan-nxki', 'fam-trastuzumab', 'enhertu', 'breast', 'trastuzumab deruxtecan']
today at 2:30 pm et #aacr23 join #fdaoncology for this discussion of the approval of fam-trastuzumab deruxtecan-nxki (enhertu) for the treatment of adult patients with unresectable or metastatic her2-low (ihc 1+ or ihc 2+/ish-) breast cancer. 
FDA Oncology Center of Excellence expedites medical product development to improve the lives of people with cancer.